secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001193125-22-207806
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics enters ATM with Jefferies for up to $75M; terminates B. Riley facility
--------------------------------------------------------------------------------

- Enters Open Market Sale Agreement with Jefferies to sell up to $75M of common stock via ATM offering.
- Prior ATM agreement with B. Riley Securities terminated effective July 29, 2022.
- Jefferies receives up to 3% commission and up to $75K expense reimbursement; Compass not obligated to sell.
- Sales will be made under effective S-3 registration statement (333-257821) and prospectus supplement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000119312522207806/0001193125-22-207806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000119312522207806/d379291d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-207806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer